PURPOSE: On the basis of the finding of marked overexpression in angiogenic microvessels, aminopeptidase N/CD13 has recently been suggested to play a prominent role in tumor angiogenesis. A soluble form of CD13 (sCD13) is present in human plasma, but its role in cancer has not been addressed. We hypothesized that sCD13 would be shed by tumor cells and/or endothelial cells lining tumor vessels, giving high levels of sCD13 in intratumoral fluid (TF) deposits and in malignant effusions. If so, sCD13 could be a convenient potential marker for tumor load and/or activated tumor endothelium. EXPERIMENTAL DESIGN: We have measured the specific sCD13 activity in effusions from 90 cancer patients and 12 patients with a nonmalignant condition, and studied its relationship with other major (anti-)angiogenic factors. In a separate group of patients (n = 41), the relationship of sCD13 activity in plasma with tumor load was studied. RESULTS: The sCD13 activity was highest in plasma from cancer patients 71.9 (fmol/ml/s hydrolyzed substrate) versus 42.4 for healthy subjects. In TF, malignant effusions, and nonmalignant effusions, the activities were 52.8, 33.5, and 18.6, respectively. We further studied the relationship of sCD13 with tumor load as well as with vascular endothelial growth factor (VEGF), endostatin, matrix metalloproteinase (MMP)-2, MMP-9, urokinase-type plasminogen activator, and plasmin. A significant correlation of sCD13 activity in plasma was found with tumor load (r = 0.68; P = 0.01), suggesting that plasma sCD13 is, at least, partly originating from tumor(-endothelium). The concentrations of VEGF and endostatin and the activities of urokinase-type plasminogen activator and MMP-9, but not MMP-2, were significantly higher in TF compared with all other effusions. In TF, a correlation between sCD13 and VEGF was found (r = 0.67; P = 0.03). No correlation of sCD13 with the other protease activities was found. CONCLUSION: The sCD13 activity is elevated in plasma and effusions of cancer patients. A strong correlation of plasma sCD13 with tumor load was found. On the basis of these results, the potential of sCD13 activity as a tumor and/or angiogenesis marker warrants further investigation.
PURPOSE: On the basis of the finding of marked overexpression in angiogenic microvessels, aminopeptidase N/CD13 has recently been suggested to play a prominent role in tumor angiogenesis. A soluble form of CD13 (sCD13) is present in human plasma, but its role in cancer has not been addressed. We hypothesized that sCD13 would be shed by tumor cells and/or endothelial cells lining tumor vessels, giving high levels of sCD13 in intratumoral fluid (TF) deposits and in malignant effusions. If so, sCD13 could be a convenient potential marker for tumor load and/or activated tumor endothelium. EXPERIMENTAL DESIGN: We have measured the specific sCD13 activity in effusions from 90 cancerpatients and 12 patients with a nonmalignant condition, and studied its relationship with other major (anti-)angiogenic factors. In a separate group of patients (n = 41), the relationship of sCD13 activity in plasma with tumor load was studied. RESULTS: The sCD13 activity was highest in plasma from cancerpatients 71.9 (fmol/ml/s hydrolyzed substrate) versus 42.4 for healthy subjects. In TF, malignant effusions, and nonmalignant effusions, the activities were 52.8, 33.5, and 18.6, respectively. We further studied the relationship of sCD13 with tumor load as well as with vascular endothelial growth factor (VEGF), endostatin, matrix metalloproteinase (MMP)-2, MMP-9, urokinase-type plasminogen activator, and plasmin. A significant correlation of sCD13 activity in plasma was found with tumor load (r = 0.68; P = 0.01), suggesting that plasma sCD13 is, at least, partly originating from tumor(-endothelium). The concentrations of VEGF and endostatin and the activities of urokinase-type plasminogen activator and MMP-9, but not MMP-2, were significantly higher in TF compared with all other effusions. In TF, a correlation between sCD13 and VEGF was found (r = 0.67; P = 0.03). No correlation of sCD13 with the other protease activities was found. CONCLUSION: The sCD13 activity is elevated in plasma and effusions of cancerpatients. A strong correlation of plasma sCD13 with tumor load was found. On the basis of these results, the potential of sCD13 activity as a tumor and/or angiogenesis marker warrants further investigation.
Authors: Josep Villanueva; David R Shaffer; John Philip; Carlos A Chaparro; Hediye Erdjument-Bromage; Adam B Olshen; Martin Fleisher; Hans Lilja; Edi Brogi; Jeff Boyd; Marta Sanchez-Carbayo; Eric C Holland; Carlos Cordon-Cardo; Howard I Scher; Paul Tempst Journal: J Clin Invest Date: 2006-01 Impact factor: 14.808
Authors: Yuxuan Du; Chenyang Lu; Rachel L Morgan; William A Stinson; Phillip L Campbell; Ellen Cealey; Wenyi Fu; Nicholas J Lepore; Jonatan L Hervoso; Huadong Cui; Andrew G Urquhart; Jeffrey N Lawton; Kevin C Chung; David A Fox; Mohammad A Amin Journal: J Immunol Date: 2019-06-12 Impact factor: 5.422
Authors: A H G Hansma; Y van Hensbergen; B C Kuenen; P J van Diest; R Hanemaaijer; S Meijer; H M Pinedo; K Hoekman Journal: J Clin Pathol Date: 2004-05 Impact factor: 3.411
Authors: Hisaki Fujii; Geoff Cuvelier; Kevin She; Soudabeh Aslanian; Hiromi Shimizu; Amina Kariminia; Mark Krailo; Zhengjia Chen; Rob McMaster; Axel Bergman; Frederick Goldman; Stephen A Grupp; Donna A Wall; Andrew L Gilman; Kirk R Schultz Journal: Blood Date: 2007-10-09 Impact factor: 22.113
Authors: Jennifer M Taylor; Mariana Yaneva; Kevin Velasco; John Philip; Hediye Erdjument-Bromage; Irina Ostrovnaya; Hans G Lilja; Bernard H Bochner; Paul Tempst Journal: Proteomics Clin Appl Date: 2014-03-31 Impact factor: 3.494